Microsoft powerpoint - evaluations.ppt [compatibility mode]
IARC Monographs on the Evaluation of Carcinogenic
IARC Monograph Evaluations
experimental animals
other relevant data
Sufficient evidence
Sufficient evidence
• Mechanistic data "weak,"
Limited evidence
Limited evidence
"moderate," or "strong"?
Inadequate evidence
Inadequate evidence
Evidence suggesting lack of
Evidence suggesting lack of
• Mechanism likely to be
operative in humans?
Overall evaluation
Carcinogenic to humans
Probably carcinogenic to humans
Possibly carcinogenic to humans
Not classifiable as to its carcinogenicity to humans
Probably not carcinogenic to humans
Evaluating human data
experimental animals
other relevant data
— Preamble Part B, Section 6(a)
Causal relationship has been established
Sufficient evidence
Chance, bias, and confounding could be ruled out with
reasonable confidence
Causal interpretation is credible
Limited evidence
Chance, bias, or confounding could not be ruled out
Inadequate evidence
Studies permit no conclusion about a causal association
Several adequate studies covering the full range of
Evidence suggesting
exposure levels are mutually consistent in not showing a
lack of carcinogenicity
positive association at any observed level of exposure
Conclusion is limited to cancer sites and conditions studied
Identifying human tumour sites
Sufficient evidence
There is sufficient evidence in humans for the carcinogenicity of
tobacco smoking. Tobacco smoking causes cancer of the lung,
oral cavity, naso-, oro- and hypopharynx,.
Sufficient evidence and ESLC
There is sufficient evidence in humans for the carcinogenicity of
tamoxifen. Tamoxifen causes cancer of the endometrium. An
inverse relationship has been established between exposure to
tamoxifen and cancer of the female breast.
There is limited evidence in humans for the carcinogenicity of
Ethylene Oxide. A positive association has been observed between
exposure to Ethylene Oxide and cancers of the breast and
lymphatic and haematopoietic malignancies.
Evaluating experimental animal data
experimental animals
other relevant data
— Preamble Part B, Section 6(b)
Causal relationship has been established through either:
Sufficient evidence
- Multiple positive results (2 species, studies, sexes of GLP)- Single unusual result (incidence, site/type, age, multi-site)
Data suggest a carcinogenic effect but: (e.g.) single study,
Limited evidence
benign tumours only, promoting activity only
Inadequate evidence
Studies permit no conclusion about a carcinogenic effect
Adequate studies in at least two species show that the
Evidence suggesting
agent is not carcinogenic
lack of carcinogenicity Conclusion is limited to the species, tumour sites, age at
exposure, and conditions and levels of exposure studied
Identifying animal tumour sites
The Working Group considers that a causal relationship has been
established between the agent and an increased incidence of
malignant neoplasms or of an appropriate combination of benign and
malignant neoplasms originating from the same organ in (a) two or
more species of animals or (b) two or more independent studies in
one species carried out at different times or in different laboratories
or under different protocols.
An increased incidence of tumours originating from the same organ in
both sexes of a single species in a well-conducted study, ideally
conducted under Good Laboratory Practices, can also provide
A single study in one species and sex might be considered to provide
sufficient evidence of carcinogenicity to identify tumour sites when
malignant neoplasms occur to an unusual degree with regard to
incidence, site, type of tumour or age at onset, or when there are
strong findings of tumours at multiple sites.
Applying these criteria for the evaluation of carcinogenicity to a species
and target site-specific level, the WG identifies sites established as
causally related.
Evaluating mechanistic and other data
experimental animals
other relevant data
— Preamble Part B, Section 6(c)
Have the mechanistic events been established? Are there
• Are the mechanistic
consistent results in different experimental systems? Is
the overall database coherent?
Has each mechanism been challenged experimentally? Do
studies demonstrate that suppression of key mechanistic
processes leads to suppression of tumour development?
Are there alternative explanations? Could different
• Is the mechanism
mechanisms operate in different dose ranges, in humans
likely to be operative
and experimental animals, or in a susceptible group?
Note: an uneven level of support for different mechanisms
may reflect only the resources focused on each one
experimental animals
other relevant data
Sufficient evidence
Sufficient evidence
• Mechanistic data "weak,"
Limited evidence
Limited evidence
"moderate," or "strong"?
Inadequate evidence
Inadequate evidence
Evidence suggesting lack of
Evidence suggesting lack of
• Mechanism likely to be
operative in humans?
Overall evaluation
Carcinogenic to humans
Probably carcinogenic to humans
Possibly carcinogenic to humans
Not classifiable as to its carcinogenicity to humans
Probably not carcinogenic to humans
The plenary sessions will combine the
human and experimental evaluations
EVIDENCE IN EXPERIMENTAL ANIMALS
Group 1 (carcinogenic to humans)
Group 2B (possibly carcinogenic)
(exceptionally, Group 2A)
Group 3 (not classifiable)
Mechanistic data can be pivotal when the
human data are not conclusive
EVIDENCE IN EXPERIMENTAL ANIMALS
1 strong evidence
in 2A belongs to a mechanistic class where other members are
classified in Groups 1 or 2A
Group 2B (exceptionally, Group 2A)
1 strong evidence
in 2A belongs to a
2A belongs to a
mechanistic class
mechanistic class
2A strong evidence 2B with supporting 2B with strong
… mechanism also
operates in humans
other relevant data
other relevant data
4 consistently and
3 strong evidence …
strongly supported
by a broad range of
other relevant data
Diesel engine exhaust (V 105)
The Working Group concluded that there was
"sufficient evidence" in humans for the carcinogenicity of
diesel-engine exhaust.
"sufficient evidence" in experimental animals for the
carcinogenicity of whole diesel-engine exhaust, of diesel-
engine exhaust particles and of extracts of diesel-engine
exhaust particles.
"strong evidence" for the ability of whole diesel-engine
exhaust to induce cancer in humans through genotoxicity.
Overall evaluation
Diesel engine exhaust is carcinogenic to humans (Group 1)
Polychlorinated biphenyls (V 107)
The Working Group concluded that there was
"sufficient evidence" in humans for the carcinogenicity of
polychlorinated biphenyls.
"sufficient evidence" in experimental animals for the
carcinogenicity of PCB126, PCB118, Aroclor 1260, Aroclor 1254,
and Kanechlor 500.
Strong evidence of an AhR-mediated mechanism of
carcinogenesis identical to that of 2,3,7,8-TCDD.
Overall evaluation
Polychlorinated biphenyls are carcinogenic to humans (Group 1)
Dioxin-like polychlorinated biphenyls are carcinogenic to humans
Shift-work, Overall Evaluation Vol. 98
6.1 Cancer in humans
There is limited evidence in humans for the
carcinogenicity of shiftwork that involves night
6.2 Cancer in experimental animals
There is sufficient evidence in experimental animals
for the carcinogenicity of light during the daily dark
period (biological night).
6.3 Overall evaluation
Shiftwork that involves circadian disruption is
probably carcinogenic to humans (Group 2A)
Arsenic, Vol 84, Section 3
There is limited evidence in experimental
animals for the carcinogenicity of sodium
arsenite, calcium arsenate and arsenic trioxide.
There is inadequate evidence in experimental
animals for the carcinogenicity of sodium
arsenate and arsenic trisulfide.
Taken together, the studies on inorganic arsenic
provide limited evidence for carcinogenicity in
Lead, Vol. 97, Section 3
There is sufficient evidence in experimental
animals for the carcinogenicity of lead acetate,
lead subacetate, lead chromate, and lead
There is inadequate evidence in experimental
animals for the carcinogenicity of lead oxide and
There is sufficient evidence in experimental
animals for the carcinogenicity of inorganic lead
"The categorization of an agent is a matter
of scientific judgement . ."
"It is recognized that the criteria for these evaluations cannot
encompass all of the factors that may be relevant to an evaluation
of carcinogenicity. In considering all of the relevant scientific data,
the Working Group may assign the agent to a higher or lower
category than a strict interpretation of these criteria would indicate."
"These categories refer only to the strength of the evidence that an
exposure is carcinogenic and not to the extent of its carcinogenic
activity (potency)."
Preamble Part B, Section 6
"The distinction between hazard and risk is important, and the
Monographs identify cancer hazards even when risks are very low at
current exposure levels, because new uses or unforeseen exposures
could engender risks that are significantly higher."
Preamble Part A, Section 2
You may apply an evaluation to a broad
grouping of agents or to one specific agent
"When the agents evaluated are considered by the Working Group to be
sufficiently closely related, they may be grouped together for the purpose of
a single evaluation of degree of evidence."
Preamble Part B, Section 6
"In addition, when supporting data indicate that other related agents, for
which there is no direct evidence of their capacity to induce cancer in
humans or in animals, may also be carcinogenic, a statement describing the
rationale for this conclusion is added to the evaluation narrative; an
additional evaluation may be made for this broader group of agents . ."
Preamble Part B, Section 6(d)
"When the available epidemiological studies pertain to a mixture, process,
occupation or industry, the Working Group seeks to identify the specific
agent considered most likely to be responsible for any excess risk. The
evaluation is focused as narrowly as the available data on exposure and
other aspects permit."
Preamble Part B, Section 6(a)
Guidance can be found in the Preamble
"The Preamble to the IARC Monographs describes the objective
and scope of the programme, the scientific principles and procedures
used in developing a Monograph, the types of evidence considered,
and the scientific criteria that guide the evaluations."
A. GENERAL PRINCIPLES AND PROCEDURES
WORLD HEALTH ORGANIZATION
INTERNATIONAL AGENCY FOR RESEARCH ON CANCER
2. Objective and scope
3. Selection of agents for review
IARC Monographs on the Evaluation of
Carcinogenic Risks to Humans
4. Data for the Monographs
5. Meeting participants
6. Working procedures
B. SCIENTIFIC REVIEW AND EVALUATION
P R E A M B L E
2. Studies of cancer in humans
3. Studies of cancer in experimental animals
LYON, FRANCE
4. Mechanistic and other relevant data
6. Evaluation and rationale
The text should present the
Working Group's reasoning
Concise statements of the principal line(s) of argument that emerge
Conclusions of the Working Group on the strength of the evidence
for each group of studies
Citations to indicate which studies were pivotal to these conclusions
Explanation of the reasoning of the Working Group in weighing data
and making evaluations
— Preamble Part B, Section 6(e)
experimental animals
other relevant data
Sufficient evidence
Sufficient evidence
• Mechanistic data "weak,"
Limited evidence
Limited evidence
"moderate," or "strong"?
Inadequate evidence
Inadequate evidence
Evidence suggesting lack of
Evidence suggesting lack of
• Mechanism likely to be
operative in humans?
Overall evaluation
Carcinogenic to humans
Probably carcinogenic to humans
Possibly carcinogenic to humans
Not classifiable as to its carcinogenicity to humans
Probably not carcinogenic to humans
Source: http://www.febev.be/article-attachment.cfm?page=download&attachmentid=776430CF-30E1-413B-9D07-637BDBEA35A9&type=page&lang=nl
NORGESTOMET AND ESTRADIOL VALERATE INDUCED LUTEOLYSIS IS DEPENDENT UPON THE UTERUS C. A. Peterson, J. C. Huhn, and D. J. Kesler SUMMARY Beef heifers were assigned to three groups: 1) untreated controls (n= 4), 2) Syncro-Mate B® (SMB) treated (n= 5), and 3) hysterectomized and SMB treated (n= 4). SMB was administered eight or nine days after estrus, approximately 30 days after hysterectomy. This study was conducted to determine if the uterus was necessary for SMB to induce luteolysis. SMB induced premature luteolysis as only 20% of the intact SMB treated heifers had ≥ .75 ng/mL of progesterone seven days after the time of SMB treatment compared to all (100%) of the untreated heifers (P <.05). By nine days after the time of SMB treatment, 25% of the untreated heifers and none (0%) of the intact SMB treated heifers had ≥ .75 ng/mL of progesterone; however, all (100%) of the hysterectomized SMB treated heifers had ≥ .75 ng/mL of progesterone (P <.05). Therefore, SMB-induced luteolysis required the involvement of the uterus. The luteolysin, prostaglandin F2α, is probably the secretion from the uterus that mediates the SMB-induced luteolysis. SMB treatment, however, required 7-8 days to induce luteolysis. INTRODUCTION Syncro-Mate B® (SMB) is a commercially available procedure to synchronize estrus in beef and dairy cattle. The procedure consists of a norgestomet implant and an intramuscular injection containing norgestomet and estradiol valerate administered at the time of implantation. SMB has three known mechanisms of action. First, an estrus suppression dosage of norgestomet diffuses from the implant during the nine days in situ (Kesler and Favero, 1995). Secondly, the injection causes atresia of antral follicles and recruitment of a new cohort of follicles four to five days after administration (Vasconcelos et al., 1997). Thirdly, the injection causes regression of corpora lutea (Kesler and Favero, 1995). Since the implant is left in place for nine days, the injection is needed to induce regression of corpora lutea in cows during the first half of the estrous cycle. Estradiol-17β, the active metabolite of the estradiol valerate contained within the SMB injection, has been demonstrated to hasten corpus luteum regression (Thatcher et al., 1986). Thatcher et al. (1986) reported spikes of 15-keto- 13, 14-dihydro-prostaglandin F2α (PGFM) in the peripheral blood before luteolysis ensued and concluded that estradiol-17β induced luteolysis by provoking a release of PGF2α from the uterus; however, Thatcher et al. (1986) administered estradiol-17β during the second half of the estrous cycle. Progesterone treatment during metestrus has also been reported to shorten the estrous cycle, but only by four days (Woody et al., 1967; Harms and Malven, 1969; Ginther, 1970; Battista et al., 1984; Garrett et al., 1988). The objective of this study was to determine if the hypothesis that SMB induced luteolysis is dependent upon uterine involvement was correct. MATERIALS AND METHODS Three groups of purebred Angus beef heifers from the University of Illinois beef research unit (Urbana, IL) were included in this study. The control group (n=4) was selected from a larger group of estrus-cycling females administered prostaglandin F2α (25 mg Lutalyse®; Pharmica and Upjohn, Kalamazoo, MI, USA) due to their similar timing of estrus (detectable estrus within 48 hours of each
AP® STATISTICS 2011 SCORING GUIDELINES (Form B) Question 2 Intent of Question The primary goals of this question were to assess students' ability to (1) distinguish an experiment from an observational study; (2) critique statistical information, in particular whether or not researchers are justified in making a specific conclusion based on the given information; (3) recognize and describe a potential problem with a study that lacks random assignment or blinding. Solution Part (a):